{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:31:39Z","timestamp":1790775099206,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinical-colorectal-cancer.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clcc.2024.03.001","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T15:33:01Z","timestamp":1711985581000},"page":"118-127.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable\/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-844X","authenticated-orcid":false,"given":"Richard","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Tehfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Kortmansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Predoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Gabriela","family":"Chiorean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2024.03.001_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2024.03.001_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0004","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0005","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O'Neil","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2024.03.001_bib0006","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/j.annonc.2020.08.640","article-title":"High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated mismatch repair proficient (MMRp) advanced tumours","volume":"31","author":"Rousseau","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11864-015-0348-2","article-title":"Microsatellite instability testing and its role in the management of colorectal cancer","volume":"16","author":"Kawakami","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0008","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2024.03.001_bib0009","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0010","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1634\/theoncologist.2018-0344","article-title":"Phase II randomized trial of sequential or concurrent FOLFOXIRI-bevacizumab versus FOLFOX-bevacizumab for metastatic colorectal cancer (STEAM)","volume":"24","author":"Hurwitz","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2024.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0012","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2024.03.001_bib0013","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0014","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"Xu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0015","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/annonc\/mdv197","article-title":"FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study","volume":"26","author":"Iwamoto","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0016","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12032-013-0486-y","article-title":"FOLFIRI\u202f+\u202fbevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials","volume":"30","author":"Beretta","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0017","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0018","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0019","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clcc.2024.03.001_bib0020","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-21-3329","article-title":"Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types","volume":"28","author":"Cristescu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2024.03.001_bib0021","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.clcc.2024.03.001_bib0022","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2017.35.15_suppl.3541","article-title":"A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer","volume":"35","author":"Shahda","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2022.40.4_suppl.008","article-title":"Nivolumab (NIVO)\u202f+\u202f5-fluorouracil\/leucovorin\/oxaliplatin (mFOLFOX6)\/bevacizumab (BEV) versus mFOLFOX6\/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): phase 2 results from CheckMate 9X8","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0024","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2024.03.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clcc.2024.03.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clcc.2024.03.001_bib0027","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clcc.2024.03.001_bib0028","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ijc.31107","article-title":"Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability","volume":"142","author":"Korehisa","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2024.03.001_bib0029","doi-asserted-by":"crossref","first-page":"e23810","DOI":"10.1002\/jcla.23810","article-title":"Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment","volume":"35","author":"Bai","year":"2021","journal-title":"J Clin Lab Anal"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T12:52:54Z","timestamp":1717332774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002824000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1533002824000239"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2024.03.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable\/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2024.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}